BIOA — Bioiasis AD Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.16% | ||
| Return on Equity | 80.22% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | BGNm | n/a | n/a | n/a | 0.01 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bioiasis AD is a Bulgaria-based company that specializes in the wholesale of biomaterial products surgical supplies such as medicines, medical materials and instruments, sanitary and hygienic products, disinfectants, medical cosmetics and appliances, as well as medical equipment and consumables. The Company distributes cardiology products like Paclitaxel Eluting Balloon and Paclitaxel Eluting Stent; orthopedics products like Lineage Acetabular Cups, Advance Medical Pivot Knee and Olympia Total Shoulder System; neurosurgery products like pressure valve, mano-pressure valve, cervical disc, cervical cage and anterior cervical plate; and hemostasis products like haemostatic gauze, haemostatic powder and resorbable collagen hemostat. The Company distributes its products nationally and internationally, in Bulgaria, Greece, Cyprus, Romania, Serbia, the Russian Federation and the United States.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 18th, 2005
- Public Since
- May 8th, 2008
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Bulgarian Stock Exchange
- Shares in Issue
- 1,171,215
- Address
- 70, Ralevitsa Str., Atelier 1, SOFIA, 1618
- Web
- https://www.bioiasis.com/
- Phone
- +359 24807788
- Auditors
- ABABILL GER5 ODIT EOOD
Upcoming Events for BIOA
Similar to BIOA
Etropal AD
Bulgarian Stock Exchange
Momina Krepost AD
Bulgarian Stock Exchange
FAQ
As of Today at 10:36 UTC, shares in Bioiasis AD are trading at BGN16.08. This share price information is delayed by 15 minutes.
Shares in Bioiasis AD last closed at BGN16.08 and the price had moved by -18.38% over the past 365 days. In terms of relative price strength the Bioiasis AD share price has underperformed the FTSE Global All Cap Index by -21.98% over the past year.
There is no consensus recommendation for this security.
Find out moreBioiasis AD does not currently pay a dividend.
Bioiasis AD does not currently pay a dividend.
Bioiasis AD does not currently pay a dividend.
To buy shares in Bioiasis AD you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of BGN16.08, shares in Bioiasis AD had a market capitalisation of .
Here are the trading details for Bioiasis AD:
- Country of listing: Bulgaria
- Exchange: BLG
- Ticker Symbol: BIOA
Based on an overall assessment of its quality, value and momentum Bioiasis AD is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioiasis AD. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -12.48%.
As of the last closing price of BGN16.08, shares in Bioiasis AD were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bioiasis AD PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at BGN16.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bioiasis AD's management team is headed by:
- Gergana Yordanova - CEO
- Dimitrios Dumbalis - DRC
- Paraskevi Kisas - DRC